Health Economics›Colorectal cancer›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Colorectal cancer · 65 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 41 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	MSI-H	R 286 955	14d	16.5 mo	77.5 mo	2	R 573 911 PFS proxy	3
Ipilimumab and Nivolumab Variant #01 Partial	MSI-H	R 78 615	42d	—	~18.2 mo	~9	~R 707 538 PFS proxy · indirect	2
mFOLFOX6 and Cetuximab Variant #03	RAS	R 57 509	14d	8.2 mo	30.9 mo	3	R 87 490 PFS proxy	4
FOLFIRI and Cetuximab Variant #01	RAS	R 57 190	14d	8.9 mo	30.9 mo	3	R 86 532 PFS proxy	5
FOLFOX4 and Cetuximab Variant #01	RAS	R 56 943	14d	9.2 mo	22.1 mo	3	R 85 791 PFS proxy	3
FOLFIRI and Cetuximab (L-Leucovorin) Variant #01 Partial	RAS	R 56 627	14d	—	23.5 mo	3	R 84 843 PFS proxy	1
CapeOx and Panitumumab Variant #01	RAS	R 40 501	21d	—	—	~2	~R 81 002 indirect	—
IFL and Bevacizumab Variant #01	—	R 37 220	21d	8.3 mo	19.5 mo	2	R 74 440 PFS proxy	3
Atezolizumab monotherapy Variant #01	MSI-H	R 31 255	21d	~12.9 mo	~13.3 mo	~2	~R 62 509 PFS proxy · indirect	10
Capecitabine and Bevacizumab Variant #01	—	R 31 025	21d	9.2 mo	—	2	R 62 050 PFS proxy	4
FOLFOXIRI and Panitumumab Variant #01	RAS	R 28 734	14d	—	—	~3	~R 86 202 indirect	—
mFOLFOX6 and Panitumumab Variant #01	RAS	R 27 871	14d	12.8 mo	37.4 mo	2	R 55 742 PFS proxy	3
FOLFOX4 and Panitumumab Variant #01	RAS	R 27 868	14d	9.6 mo	23.8 mo	2	R 55 735 PFS proxy	2
mFOLFOXIRI and Cetuximab (L-Leucovorin) Variant #01 Partial	RAS	R 26 156	14d	—	—	~8	~R 209 246 indirect	—
IRIS and Bevacizumab Variant #01 Partial	—	R 23 619	21d	14.0 mo	—	2	R 47 237 PFS proxy	1
FOLFOX4 and Bevacizumab Variant #01	—	R 21 696	14d	—	~12.9 mo	~2	~R 43 391 PFS proxy · indirect	1
CAPIRI-Bev Variant #01	—	R 18 904	21d	10.2 mo	—	6	R 113 421 PFS proxy	—
SOX and Bevacizumab Variant #01 Partial	—	R 17 937	21d	11.7 mo	—	2	R 35 875 PFS proxy	1
FOLFIRINOX and Bevacizumab Variant #01	—	R 14 987	14d	11.5 mo	—	12	R 179 850 PFS proxy	1
FOLFIRI and Bevacizumab Variant #01	—	R 14 447	14d	7.6 mo	32.4 mo	2	R 28 895 PFS proxy	4
FOLFIRI and Bevacizumab Variant #01	RAS	R 14 447	14d	7.6 mo	32.4 mo	2	R 28 895 PFS proxy	4
FOLFIRI and Bevacizumab Variant #01	MSI-H	R 14 447	14d	7.6 mo	32.4 mo	2	R 28 895 PFS proxy	4
FOLFIRINOX and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 13 861	14d	12.1 mo	31.0 mo	8	R 110 891 PFS proxy	2
mFOLFOX6-B Variant #01	—	R 13 521	14d	10.1 mo	29.0 mo	9	R 121 686 PFS proxy	10
mFOLFOX6-B Variant #01	RAS	R 13 521	14d	10.1 mo	29.0 mo	9	R 121 686 PFS proxy	10
mFOLFOX6-B Variant #01	MSI-H	R 13 521	14d	10.1 mo	29.0 mo	9	R 121 686 PFS proxy	10
FULV and Bevacizumab Variant #02	—	R 13 379	14d	—	—	~2	~R 26 757 indirect	—
mFOLFOX6-B (L-Leucovorin) Variant #01 Partial	—	R 12 958	14d	11.2 mo	—	12	R 155 492 PFS proxy	2
CapeOx and Bevacizumab Variant #01	—	R 12 911	21d	10.3 mo	—	12	R 154 931 PFS proxy	4
FOLFIRI and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 12 900	14d	10.9 mo	25.8 mo	2	R 25 799 PFS proxy	3
FOLFIRI Variant #05	RAS	R 11 525	14d	8.4 mo	19.5 mo	2	R 23 051 PFS proxy	13
FOLFIRI Variant #05	MSI-H	R 11 525	14d	8.4 mo	19.5 mo	2	R 23 051 PFS proxy	13
FOLFIRI Variant #05	—	R 11 525	14d	8.4 mo	19.5 mo	2	R 23 051 PFS proxy	13
FULV and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 11 268	14d	9.4 mo	—	2	R 22 536 PFS proxy	1
FUFOX Variant #01	—	R 7 901	35d	8.0 mo	—	2	R 15 801 PFS proxy	1
FOLFOX2 Variant #01	—	R 4 584	14d	—	18.7 mo	2	R 9 168 PFS proxy	1
FOLFOX 7/sLV5FU2 Variant #01	—	R 3 941	14d	—	—	~6	~R 23 645 indirect	—
FULV Variant #29	—	R 3 601	14d	6.2 mo	13.1 mo	2	R 7 201 PFS proxy	6
FOLFIRINOX Variant #03	RAS	R 3 520	14d	—	22.6 mo	2	R 7 041 PFS proxy	1
FOLFIRINOX Variant #03	—	R 3 520	14d	—	22.6 mo	2	R 7 041 PFS proxy	1
mFOLFOX7 Variant #01	—	R 3 281	14d	—	—	~6	~R 19 685 indirect	—
CAPIRI Variant #05	—	R 2 849	21d	5.9 mo	—	9	R 25 642 PFS proxy	1
IROX Variant #01	—	R 2 774	21d	—	~13.4 mo	~2	~R 5 548 PFS proxy · indirect	1
Irinotecan monotherapy Variant #01	—	R 2 716	42d	—	~10.9 mo	~11	~R 29 874 PFS proxy · indirect	4
CapeOx Variant #01	—	R 2 620	21d	6.9 mo	19.9 mo	2	R 5 240 PFS proxy	2
mFOLFOX6 Variant #02	MSI-H	R 2 617	14d	9.5 mo	23.3 mo	6	R 15 700 PFS proxy	6
mFOLFOX6 Variant #02	—	R 2 617	14d	9.5 mo	23.3 mo	6	R 15 700 PFS proxy	6
FOLFOX4 Variant #01	RAS	R 2 374	14d	8.2 mo	19.4 mo	3	R 7 122 PFS proxy	6
FOLFOX4 Variant #01	—	R 2 374	14d	8.2 mo	19.4 mo	3	R 7 122 PFS proxy	6
FOLFIRI (L-Leucovorin) Variant #01 Partial	—	R 2 297	14d	8.4 mo	17.0 mo	2	R 4 595 PFS proxy	2
IFL Variant #01	—	R 2 214	21d	4.2 mo	15.4 mo	2	R 4 428 PFS proxy	2
FOLFOX6 Variant #01	—	R 2 212	14d	6.7 mo	—	2	R 4 424 PFS proxy	—
mFOLFOX7 (L-Leucovorin) Variant #01 Partial	—	R 2 155	14d	—	—	~6	~R 12 928 indirect	—
OXAFAFU Variant #01	—	R 2 110	14d	—	18.9 mo	2	R 4 221 PFS proxy	—
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 2 054	14d	—	23.3 mo	12	R 24 643 PFS proxy	1
Nordic FLOX Variant #01	—	R 1 990	14d	—	—	~8	~R 15 918 indirect	—
FUOX Variant #01	—	R 1 629	14d	—	~10.6 mo	~18	~R 29 321 PFS proxy · indirect	—
FOLFOX4 (L-Leucovorin) Variant #01 Partial	—	R 1 487	14d	6.7 mo	—	2	R 2 975 PFS proxy	2
SOX Variant #01 Partial	—	R 1 265	21d	8.5 mo	—	2	R 2 530 PFS proxy	1
Capecitabine monotherapy Variant #01	—	R 1 039	21d	5.7 mo	—	35	R 36 351 PFS proxy	3
FUIRI Variant #01	—	R 967	7d	—	—	~2	~R 1 935 indirect	—
Fluorouracil monotherapy Variant #01	—	R 647	28d	—	10.0 mo	2	R 1 294 PFS proxy	—
FULV (L-Leucovorin) Variant #06 Partial	—	R 61	14d	—	~6.1 mo	~30	~R 1 820 PFS proxy · indirect	1
S-1 monotherapy Variant #01 Partial	—	—	21d	~1.7 mo	~10.5 mo	~2	—	13
FOLFOX 7/sLV5FU2 (L-Leucovorin) Partial	—	—	—	—	—	—	—	—

65 of 65 regimens shown